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A B S T R A C T   
Chromatin remodeling, and a persistent histone 3 lysine 27 acetylation (H3K27ac) in particular, are associated 
with a sustained inflammatory response of synovial fibroblasts (SF) in rheumatoid arthritis (RA). Here we 
investigated individual functions of the writers of H3K27ac marks, the homologues histone acetyl transferases 
(HAT) CBP and p300, in controlling the constitutive and inflammatory gene expression in RA SF. We applied a 
silencing strategy, followed by RNA-sequencing and pathway analysis, complemented with the treatment of SF 
with inhibitors targeting the HAT (C646) or bromo domains (I-CBP) of CBP and p300. We showed that CBP and 
p300 undertook overlapping and, in particular at gene levels, distinct regulatory functions in SF. p300 is the 
major HAT for H3K27ac in SF and regulated more diverse pathways than CBP. Whereas both factors regulated 
genes associated with extracellular matrix remodeling, adhesion and proliferation, p300 specifically controlled 
developmental genes associated with limb development. Silencing of CBP specifically down regulated the TNF- 
induced expression of interferon-signature genes. In contrast, silencing of p300 resulted in anti- and pro- 
inflammatory effects. Integration of data sets derived from RNA-sequencing and chromatin immunoprecipita-
tion sequencing for H3K27ac revealed that changes in gene expression after CBP or p300 silencing could be only 
partially explained by changes in levels of H3K27ac. Inhibition of CBP/p300 using HAT and bromo domain 
inhibitors strongly mirrored effects obtained by silencing of p300, including anti- and pro-inflammatory effects, 
indicating that such inhibitors are not sufficient to be used as anti-inflammatory drugs.   
1. Introduction 
RA is one of the most prominent chronic, inflammatory joint disease, 
causing cartilage and bone damage [1]. Intrinsically activated synovial 
fibroblasts (SF) are a key cell population that contributes to RA patho-
genesis [2]. Functional studies in vivo have demonstrated that RA SF 
invade into and destroy cartilage [3] and suggested that they are capable 
to transmigrate into the vasculature and thus spread RA to multiple 
joints [4]. Recent work has demonstrated that functionally distinct SF 
subtypes drive cartilage breakdown and promote the persistent inflam-
mation in RA [5,6]. We and others have previously shown that the 
exposure to pro-inflammatory factors induces a sustained and prolonged 
inflammatory response in SF [7,8]. Chromatin remodeling, and in 
particular persistent histone 3 lysine 27 acetylation (H3K27ac), were 
shown to be associated with the sustained TNF-induced gene expression 
in RA SF [8]. The presence of H3K27ac marks is a hallmark of active 
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enhancers and is additionally found in gene promoters [9]. Enhancers 
underlie cell-type- and stimulus-specific cell responses and can activate 
gene expression at great distances [10,11]. 
CREB-binding protein (CBP) and p300 constitute a unique group of 
histone acetyl transferases (HAT) that account for writing H3K27ac 
marks [12]. Binding of p300 to chromatin regions has been used as a 
surrogate for H3K27ac to predict the tissue-specific activity of enhancers 
[13]. However, the recruitment of CBP and p300 to chromatin regions 
only partially correlates with transcriptional activation and strongly 
depends on the genomic context [14], indicating that chromatin 
immunoprecipitation with sequencing (ChIPseq) is not sufficient to 
identify individual target genes of CBP and p300. 
CBP and p300 are multi-domain proteins that serve as co-factors for a 
wide spectrum of transcription factors and act as scaffolds for large 
protein complexes that regulate transcription [15]. They exhibit in 
addition to the HAT “writer” domain, a bromo domain as a “reader” of 
acetylated lysine residues, and E3 and E4 ligase activities for protein 
ubiquitination [15,16]. Inhibitors targeting the bromo domains of CBP 
and p300 are in drug development for malignant and inflammatory 
diseases [17]. 
Given their high degree of sequence homology, CBP and p300 are 
widely considered to have redundant functions (often referred as CBP/ 
p300). Studies in knockout mice have suggested some degree of func-
tional redundancy of the two enzymes but have additionally pointed to 
the existence of unique functions [15]. Only few studies addressed such 
enzyme-specific functions and have identified individual targets of CBP 
and p300 [18,19]. 
In the present study, our aim was to study individual functions of 
CBP and p300 and their functional domains in SF. We chose a silencing 
approach, complemented with inhibitor experiments targeting the HAT 
and bromo domains of CBP/p300. This enabled us to study the impact of 
different functional domains on the regulation of gene expression and to 
address the potential of CBP/p300 bromo domain inhibitors as anti- 
inflammatory drugs. 
2. Material and methods 
2.1. Patient samples and cell preparation 
Synovial tissues were derived from hand, shoulder and knee joints of 
RA patients undergoing joint replacement surgery at the Schulthess 
Clinic Zurich, Switzerland. All patients fulfilled the criteria for the 
classification of RA [20] or osteoarthritis (OA) [21]. The study was 
approved by the ethics committee of the Canton of Zurich, Switzerland. 
Informed consent was obtained from all patients prior the inclusion into 
the study. SF were isolated and cultured as described elsewhere [22] and 
used between passages four and eight for all experiments. The charac-
teristics of patients for the cultivation of SF are shown in Table 1. 
2.2. Silencing of CBP and p300 
1.5 × 105 SF were transfected with antisense LNA gapmeRs (12.5 
nM) targeting CBP, p300 or gapmeR control (Qiagen) using lipofect-
amine (Thermo Scientific). Twenty-four hours after transfection, cells 
were stimulated with TNF (10 ng/ml) for another 24 h. Supernatants 
were collected for ELISA and cells were harvested for RNA isolation or 
Western blotting. Knockdown of CBP and p300 was verified by real-time 
PCR and Western blotting. 
2.3. Treatment of SF with inhibitors 
SF were treated with 1 μM of the HAT inhibitor C646 or 1 μM of the 
bromodomain inhibitor I-CBP 112 (Tocris Bioscience) in absence and 
presence of TNF (10 ng/ml) for 24 h. Control SF were treated with 
matched amounts of dimethylsulfoxid. Cells (n = 6) were harvested 24 h 
after treatment. 
2.4. Real-time PCR 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and was 
reversed transcribed [23]. Real-time PCR (7900HT real-time PCR sys-
tem, Life Technologies) was performed using self-designed primers 
(Microsynth, supplementary table 1) and SYBR green (Roche). Dissoci-
ation curves and samples containing the untranscribed RNA were 
measured in parallel. Constitutively expressed human ribosomal protein 
large P0 (RPLP0) was measured for internal standard sample normali-
zation and relative mRNA expression levels were calculated by the 
comparative threshold cycle method (ΔΔCt) [24]. 
2.5. Western blotting 
Cells were lysed in Laemmli buffer (62.5 mM TrisHCl, 2 % SDS, 10 % 
Glycerol, 0.1 % Bromphenolblue, 5 mM β-mercaptoethanol). Whole cell 
lysates were separated on SDS polyacrylamide gels and electro blotted 
onto nitrocellulose membranes (Whatman). Membranes were blocked 
for 1 h in 5% (w/v) non-fat milk in TBS-T (20 mM Tris base, 137 mM 
sodium chloride, 0.1% Tween 20, pH 7.6). After blocking, the mem-
branes were probed with antibodies against CBP (Cell Signaling), p300 
(abcam), H3K27ac (abcam), H3K18ac (active motif), fibronectin 
(abcam), collagen 1 (abcam), p21 (Cell Signaling) or α-tubulin (abcam). 
As secondary antibodies, horseradish peroxidase-conjugated goat anti- 
rabbit or goat anti-mouse antibodies (Jackson ImmunoResearch) were 
used. Signals were detected using the ECL Western blotting detection 
reagents (GE Healthcare) and the Alpha Imager Software system (Alpha 
Innotech). 
2.6. RNA sequencing of SF 
Total RNA from SF was isolated using the RNeasy Mini Kit (Qiagen). 
The RNA quality and quantity were evaluated using the Agilent RNA 
6000 Nano Kit and the Agilent 2100 Bioanalyzer instrument (Agilent 
Technologies). Library preparation and RNA sequencing (RNAseq) was 
performed at the Functional Genomics Center Zurich (FGCZ). Libraries 
for RNAseq were generated using the Illumina TruSeq Stranded total 
RNA Sample Preparation Kit. The quality and quantity of the generated 
libraries was checked using the Agilent 2100 Bioanalyzer instrument 
and a DNA-specific chip. Libraries were sequenced by Illumina NovaSeq 
6000, with single read approaches (100bp). 
Table 1 
Characteristics of patients.   
RA (n = 25) OA (n = 5) 
age (years, mean (range)) 63 (45–82) 69 (53–81) 
sex (female/male) 23/2 4/1 
disease duration (years, mean (range)) 19 (2–36) ND 
RF (positive/negative) 18/3; ND 4 ND 























ND not determined, DMARDs disease modifying anti-rheumatic drugs, NSAIDs 
nonsteroidal anti-inflammatory drugs. 
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2.7. Bioinformatics analysis of RNA sequencing data 
To investigate RNAseq data, we conducted quality control (QC) using 
FASTQC [25], available online at: http://www.bioinformatics.babrah 
am.ac.uk/projects/fastqc. Reads of high quality were mapped to the 
human reference genome (hg19) using STAR [26]. We assessed counts 
per gene using Feature Counts [27]. We investigated differentially 
expressed genes (DEG) between experimental conditions using 
“DESeq2” package of Bioconductor. We removed genes present having 
less than one count and normalized the remaining counts using Variance 
Stabilizing Transformation (vsd) approach. We applied Wald test to 
assess differences between conditions. We set p ≤ 0.05 after false dis-
covery rate (FDR) adjustment as significant and annotated results using 
“annotables” package of Bioconductor. For the significantly DEG, we 
conducted pathway analysis using Gene Ontology (GO) terms and the 
“clusterProfiler” package of Bioconductor. 
For the RNAseq and ChIPseq data integration (see below), we re-run 
the DEG analysis in the “Limma” model using the “edgeR” package of 
Bioconductor. This was needed, as BETA software required this format. 
2.8. Integration of RNAseq and ChIPseq data 
ChIPseq data sets for H3K27ac in RA SF (n = 3) were generated 
previously [22]. H3K27ac peaks were annotated to nearest genes (TSS 
± 3 kb) and genomic features (5 kb flanking regions) using default 
settings in ChIPseeker package of Bioconductor [28]. We investigated 
RNAseq and ChIPseq integration in the following steps: 1) overlap, 2) 
association, and 3) integrative analysis. For step 1), we assessed the 
overlap between significant DEG (FDR p < 0.05, ± fold change > 1.5) 
and ChIPseq peaks using Venn diagrams from the “Vennerable” package 
of R. To assess the number of chromosomal intersections between 
RNAseq genes and peaks, we applied the “intersect” command from 
Bedtools [29]. In step 2), we investigated associations between ChIPseq 
peaks in our samples and features in the references genome using the 
CEAS tool from Galaxy [30]. Spearman correlation between bam files 
was assessed using DeepTools [31]. In step 3), we predicted possible 
activating or repressive functions using the BETA (Binding and Expres-
sion Target Analysis) software package using 100 kb distance [32]. 
2.9. ELISA 
IL6, IL8 (both BD Biosciences), MMP1, CXCL12, CX3CL1, CCL2, and 
CCL5 (all R&D Systems) were measured in cell culture supernatants 
using ELISA according to the manufacturer’s instructions. 
2.10. Analysis of cell death 
Cell viability of transfected SF (5000 cells/well) was analyzed in 
triplicates using the CytoTox-Glo cytotoxicity assay (Promega) and the 
Glomax Multi Detection System (Promega). 
2.11. Adhesion and proliferation assay 
Proliferation and adhesion (towards plastic) of transfected SF was 
analyzed using an impedance-based system for real-time proliferation 
and adhesion assays (xCELLigence System, Bucher Biotec AG). Cells 
were seeded into E-plates 24 h after transfection at a densitiy of 2500 
cells/well. TNF (10 ng/ml) was added simultaneously during seeding. 
Each condition was analyzed in quadruplicates. Impedance changes 
were recorded every 15 min (0–24 h) and every 30 min (24–120 h). 
Adhesion was analyzed over the first 2 h of the experiment. Since 
adhesion was different between conditions, proliferation data were 
normalized at 30 h, when SF started to proliferate after seeding. Pro-
liferation was analyzed over time (30–120 h). 
2.12. Statistical analysis 
Statistical analysis on data sets was carried out by using the Graph-
Pad Prism program (GraphPad Software, San Diego, CA). N numbers in 
all experiments represent biological samples from different patients. 
Differences between experimental groups were analyzed by analysis of 
variance (ANOVA) followed by Tukey’s multiple comparison test. Data 
that were not normally distributed, were analyzed by Friedmann test 
followed by the post hoc Dunn’s multiple comparison test. Data are 
reported as means ± standard deviations. P values < 0.05 were 
considered significant. 
3. Results 
3.1. p300 is the major writer of H3K27ac marks in SF 
To study their individual functions, we silenced CBP or p300 in SF in 
presence and absence of TNF, followed by RNAseq. Silencing was veri-
fied by Real-time PCR (Fig. 1A and B) and Western blotting (Fig. 1C). 
Principal component analysis of RNAseq data showed a clear separation 
of unstimulated and TNF-stimulated SF (PC1) and revealed a separation 
of SF silenced for p300 (PC2) from SF silenced for CBP and control SF, 
which clustered together (Fig. 1E). In line with this, silencing of p300 
affected more than five-fold more genes in unstimulated SF, and three- 
fold more genes in TNF-stimulated SF compared to SF silenced for 
CBP (Fig. 1F and G). Among the overlapping target genes, 8.1 % in 
unstimulated SF and 9.0 % in TNF-stimulated SF were regulated in 
opposite directions by CBP and p300, indicating individual functions of 
the two enzymes in a subset of overlapping target genes (Supplementary 
Fig. 2). 
The presence of TNF increased the levels of H3K27ac by 92 % 
(±39.2 %, p < 0.05), indicating substantial de novo writing of this 
activating histone mark in inflammatory conditions. Silencing of p300 
had a major impact on the levels of H3K27ac, which was decreased by 
32.7 % (±32.7 %, p < 0.05) and 61.1 % (±21.9 %, p < 0.05) in absence 
and presence of TNF, respectively. In contrast, silencing of CBP only 
slightly reduced the levels of H3K27ac by 11.3 % (±46.2 %, n.s.) and 
41.2 % (±34.3 %, n.s.) in absence and presence of TNF (Fig. 1C and D). 
In addition, we detected a decrease of H3K18ac marks, which was also 
more pronounced after silencing of p300 compared to silencing of CBP 
(Suppl. Fig. 1 A, B). 
To address the relationship between CBP, p300 and H3K27ac in 
more detail, we took advantage of our previously generated ChIPseq 
data set of H3K27ac marks in unstimulated RA SF (n = 3) [22]. The 
majority of H3K27ac marks in SF appeared in distal intergenic and 
intronic regions of the genome and only 8 % of H3K27ac peaks were 
found in a 3 kb range of gene promoters, in line with the presence of 
H3K27ac in promoter and enhancer regions [10]. Within promoter re-
gions, H3K27ac marks were more frequent in proximal compared to 
distal regions (Fig. 1J). We integrated the H3K27ac peaks with our list of 
CBP and p300 target genes. First, we assessed the overlap between CBP 
or p300 target genes with H3K27ac peaks of RA SF. 91.7 % of the CBP 
target genes and 88,5 % of p300 target genes possessed H3K27ac marks 
in their promoter or gene flanking regions, which accounted for 5 % and 
26 %, respectively, of the overall detected H3K27ac peaks in RA SF 
(Fig. 1H and I). Next, we integrated RNAseq data with H3K27ac ChIPseq 
data using BETA, enabling us to analyze the impact of far distant 
H3K27ac peaks on global CBP and p300 target gene expression. 
H3K27ac peaks were significantly enriched in genomic regions of >50 
kb distances from TSS (data not shown, p = 1.04 × 10−7), and became 
more enriched at distances of 100 kb from TSS of down regulated genes 
(p = 5.61 × 10−7), but not of up regulated genes after silencing of p300. 
Such an association was not found for CBP target genes (Fig. 1K and L). 
These data suggest that p300 promotes gene expression at far distant 
enhancers. 
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3.2. Identification of pathways regulated by CBP and p300 in SF 
To explore which pathways were specifically regulated by CBP or 
p300, we conducted a pathway analysis of RNAseq data. In unstimulated 
SF, CBP and p300 regulated core functions of SF, such as “extracellular 
matrix organization”, “DNA replication” and “cell cycle checkpoint” 
(Suppl. Table 2, Fig. 2A and B). In all three pathways, p300 regulated the 
majority of target genes, with 18.6 %–29.8 % of p300 target genes being 
co-regulated by CBP (Fig. 2C). Among the CBP target genes, 25 %–33.3 
% were specific for CBP and not co-regulated by p300, underscoring the 
individual functions of these enzymes in maintaining basic functions of 
SF on gene levels. Whereas the main function of CBP was associated with 
all aspects of cell division, p300 silencing additionally affected more 
diverse pathways, such as “regulation of RNA stability”, “ncRNA pro-
cessing”, “organ morphogenesis”, “limb development”, “WNT signaling” 
and “cell-substrate adhesion” (Suppl. Table 2, Fig. 2A and B). 
In TNF-stimulated SF, we additionally identified several pathways 
specific for either CBP or p300 silencing (Supplementary Table 2, 
Fig. 3D and E). This analysis pointed to CBP as the major regulator of 
inflammatory pathways associated with “interferons”, “response to 
virus”, “NF-kappaB signaling” and “cell chemotaxis”. The variety of 
pathways regulated by p300 was extensive, and included genes enriched 
in “developmental pathways”, “differentiation of osteoblasts and chon-
drocytes”, pathways associated with “adhesion”, “post-translational 
protein modification” and the “TNF-mediated signaling pathway”. To 
study the function of CBP and p300 in more detail, we selected some of 
these pathways for confirmatory studies. 
3.3. p300 regulates genes associated with limb development and the 
positional identity of SF 
Developmental pathways are recognized as key pathways activated 
in RA SF [22,33,34]. We identified enrichment of p300, but no CBP 
target genes in the biological process (BP) “limb development” 
(Supplementary Table 2, Fig. 3A). Consistent with our RNAseq data, we 
confirmed an increased expression of NOTCH1, WNT3 and WNT9a after 
silencing of p300 (Fig. 3B). We have previously shown that the 
joint-specific expression of transcripts in the 5′ end of the homeobox 
(HOX) HOXA and HOXD cluster in peripheral joints is determined by the 
chromatin landscape [22]. We now analyzed the role of CBP and p300 in 
the context of this joint-specific expression of HOX genes in SF from 
hands. In line with their joint-specific expression, the levels of H3K27ac 
in 5′ regions of the HOXA and the HOXD cluster were enriched in hand 
SF compared to SF from other joint locations (Fig. 3E and F). Silencing of 
CBP decreased the expression of HOXA13 and HOXD10. Silencing of 
p300 increased the expression of HOXA9 and HOXA11, but decreased 
the expression of HOXA13, HOXD10 and HOXD11 (Fig. 3C and D). 
Together these data indicate a key role of p300 in developmental 
pathways in SF and a minor role of CBP in maintaining the joint-specific 
expression of 5′end HOXA and HOXD transcripts. 
Fig. 1. Silencing of CBP and p300 effects global levels of H3K27ac and expression profiles of SF. CBP and p300 were silenced in SF in absence and presence of 
TNF (10 ng/ml, 24 h). Silencing of A. CBP and B. p300 was confirmed by Real time PCR and C. by Western blotting. Global levels of H3K27ac were analyzed by 
Western blotting using the expression of α-tubulin as an endogenous control. Representative Western blots are shown. D. Densitometric analysis of Western blots for 
H3K27ac. E. Principal component analysis of RNAseq data using samples from six different independent biological replicates. Triangles indicate SF derived from knee 
(n = 3), dots indicated SF derived from hand (n = 3). Venn diagrams indicating the number of genes regulated by CBP and p300 in F. unstimulated and G. TNF- 
stimulated SF. H3K27ac peaks annotated to H. CBP and I. p300 target genes in SF. J. Proportion of genomic regions enriched for H3K27ac marks in unstimulated SF 
(n = 3). K. and L. Integrative analysis of RNAseq and H3K27ac ChIPseq data sets using BETA (Binding and Expression Target Analysis). *p < 0.05, ***p < 0.005. 
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Fig. 2. Pathway enrichment analysis of CBP and p300 target genes. Transcriptomes were determined by RNAseq. Significantly affected genes (±fold change >
1.5, FDR <0.05) entered pathway enrichment analysis for Gene Ontology (GO) biological process (BP) in the “clusterProfiler” package of Bioconductor. Enriched GO 
BP identified after silencing of A. CBP and B. p300 in absence and D. and E. presence of TNF. Displayed pathways were selected from supplementary table 2. C. Venn 
diagrams indicating the proportion of target genes regulated by CBP and p300 in pathways that were overlapping in A. and B. 
Fig. 3. CBP and p300 regulate developmental pathways in SF. A. Heatmap of DEG (±fold change > 1.5, FDR <0.05) enriched in the biological process (BP) “limb 
development” that were identified by RNAseq of SF silenced for CBP or p300. B. Changes in mRNA expression of selected DEG was analyzed by Real-time PCR in an 
independent cohort from data shown in A (n = 8). The mRNA expression of genes in the 5′end of the C. HOXA and D. the HOXD cluster were analyzed by Real-time 
PCR in RA (black) and OA (red) SF from hand (n = 7). ChIPseq analysis of H3K27ac marks in the E. HOXA locus and F. HOXD locus in SF from hand, shoulder 
and knee. 
M. Krošel et al.                                                                                                                                                                                                                                  
Journal of Autoimmunity 123 (2021) 102709
6
3.4. CBP and p300 mediate extracellular matrix organization and 
remodeling 
Synthesis of extracellular matrix is a core function of SF [2]. Both in 
unstimulated and in TNF-stimulated SF, the BP “extracellular matrix 
organization” was among the top enriched pathways regulated by CBP 
and p300 (Fig. 2, Suppl. Table 2). This pathway partially overlapped 
with genes associated with “adhesion” and was composed of genes 
encoding extracellular matrix proteins, including collagens (COL), 
fibronectin (FN), and integrins (ITG), matrix-interacting proteins, such 
as thrombospondins (THBS), and matrix-remodeling enzymes, such as 
matrix-metalloproteinases (MMP) and ADAM metallopeptidases 
(Fig. 4A). We validated our findings from RNAseq on mRNA (Fig. 4B) 
and protein levels (Fig. 4C–F) in an independent sample set derived from 
RA and OA SF (Supplementary Fig. 3 A). Whereas the global analysis of 
the pathway “extracellular matrix organization” suggested that p300 is 
the major enzyme regulating this pathway (Fig. 4A), looking at indi-
vidual gene levels revealed overlapping and individual functions for CBP 
and p300. Whereas silencing of CBP down regulated the expression of 
THBS2 and COL6A3 more pronounced, the suppressive effect of 
silencing of p300 on THBS1, COL3A1, VCAM1, ADAMTS5 mRNA and 
FN1 and COL1 protein expression exceeded those of silencing of CBP 
(Fig. 4B, D-F). We observed the biggest differences in the roles of CBP 
and p300 regarding the regulation of MMP expression and secretion; 
silencing of p300 increased the basal and TNF-induced MMP expression 
and basal MMP1 secretion, whereas silencing of CBP suppressed the 
TNF-induced MMP expression and MMP1 secretion (Fig. 4B and C). 
3.5. CBP and p300 regulate proliferation and adhesion in SF 
Given the enrichment of pathways associated with “adhesion” and 
“cell cycle” and to test whether DEG translate into functional changes of 
SF, we analyzed SF adhesion and proliferation. In line with our pathways 
analysis of DEG, silencing of CBP and p300 down regulated SF adhesion 
in absence and presence of TNF (Fig. 5A and B). Since both factors 
affected adhesion, we normalized proliferation slopes to 30 h, the time 
point when control cells started to proliferate after seeding. Both, 
silencing of CBP and p300 decreased the proliferation of SF in absence 
and presence of TNF (Fig. 5C and D). 
The expression of p21, a potent inhibitor of cell cycle dependent 
kinases, was increased in SF upon silencing of p300 in absence and 
presence of TNF, but was not affected upon silencing of CBP (Fig. 5E and 
F). Cell death was slightly increased in p300 silenced SF in presence of 
TNF (Fig. 5G), and could therefore not account for the reduced imped-
ance measurements in all other conditions compared to control SF. 
3.6. CBP and p300 regulate the inflammatory response of SF 
Consistent with our data from RNAseq, silencing of CBP specifically 
downregulated the expression of genes that were enriched in the path-
ways “type I interferon signaling pathway” (2′-5′-Oligoadenylate Syn-
thetase 1, OAS1; Signal transducer and activator of transcription 1, 
STAT1), “response to interferon-γ” (OAS1, STAT1) and “response to 
virus” (STAT1, IL6, OAS1, CXCL10, CXCL12) (Supplementary Table 2, 
Fig. 6A). STAT1 is a master transcription factor implicated in regulating 
TNF-induced interferon response genes in SF (Fig. 6A) [35]. In line with 
the changes on mRNA levels, the secretion of CXCL12 and IL6 was 
Fig. 4. CBP and p300 regulate the extracellular matrix organization in SF. A. Heatmap of DEG (±fold change > 1.5, FDR <0.05) enriched in the biological 
process (BP) “extracellular matrix organization” that were identified by RNAseq of SF silenced for CBP or p300 in absence and presence of TNF (10 ng/ml). B. 
Changes in mRNA expression of selected DEG was analyzed by Real-time PCR in an independent cohort from data shown in A. Heatmap shows mean values of fold 
expression calculated relative to gap-ctrl based on 9–13 independent experiments. C. The secretion of MMP1 was analyzed in cell culture supernatants from RA 
(black) and OA (red) SF (n = 9) silenced for CBP or p300 in absence and presence of TNF (10 ng/ml). D. Representative Western blots showing the protein expression 
of fibronectin (FN1), collagen 1 (COL1) and the house keeping protein α-tubulin in SF silenced for CBP and p300 in absence and presence of TNF (10 ng/ml). E. and 
F. Densitometric analysis of D. *p < 0.05, **p < 0.01, ***p < 0.005. 
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decreased after silencing of CBP (Fig. 6B). 
Given the potential use of CBP/p300 inhibitors as anti-inflammatory 
drugs, we further analyzed the expression of TNF-induced cytokines and 
chemokines that we identified to be significantly changed after silencing 
of CBP and/or p300 in our RNAseq data set (Supplementary Fig. 4). 
Silencing of CBP resulted in anti-inflammatory effects, indicated by 
reduction of the TNF-induced gene expression of IL15, CX3CL1, CCL2, 
IL8 and CCL20, and the decreased secretion of CX3CL1 and CCL5 protein 
(Fig. 6C and D). In contrast, we detected pro-inflammatory (CXCL2, IL8, 
CCL20) and anti-inflammatory effects (reduction of IL15, CX3CL1, 
CCL2, CCL5) after silencing of p300 in presence of TNF (Fig. 6C, D). 
Effects of CBP and p300 silencing on the inflammatory response was 
similar in RA and OA SF for all genes analyzed (Suppl. Fig. 3B). 
To test potential effects of CBP/p300 inhibitors, we treated SF with 
TNF in absence and presence of the HAT inhibitor C646 and the bro-
modomain inhibitor I-CBP, respectively. Both inhibitors reduced the 
TNF-induced levels of H3K27ac in SF (Fig. 6E and F), indicating that 
both functional activities, the HAT and the reader (bromo-) domain of 
CBP/p300 were required for the writing of H3K27ac marks in inflam-
matory conditions. Treatment with C646 decreased the TNF-induced 
expression of VCAM1, CX3CL1, IL15, IL8, IL6, MMP1, STAT1, OAS1, 
CXCL10 and CXCL2 and thus, mirrored with the exception of CXCL2, the 
effects of CBP silencing. Treatment with I-CBP decreased the TNF- 
induced expression of genes that were either decreased by both CBP 
and p300 silencing (NOD2, CCL2, CXCL12, VCAM1, CX3CL1, IL15), or 
that were decreased by silencing of CBP and not affected by p300 
silencing (STAT1, CXCL10). In contrast, genes that were downregulated 
by silencing of CBP, but increased by silencing of p300, such as OAS1, 
IL8, MMP1, IL6 and CXCL2 exhibited an increased TNF-induced 
expression after treatment of I-CBP, indicating that I-CBP-induced ef-
fects rather mirrored those obtained by silencing of p300 than by 
silencing of CBP. 
4. Discussion 
In this study we have identified p300 as the major HAT that writes 
H3K27ac marks in SF. H3K27ac marks are activating histone marks 
present in promoters and enhancers [9]. In unstimulated cells, en-
hancers and in particular super-enhancers that are marked by the 
presence of H3K27ac, control and define cell identity [36]. In line with 
this definition, we showed that the majority of H3K27ac in unstimulated 
SF was located in distal intergenic and intronic chromatin regions, and 
Fig. 5. Silencing of CBP and p300 co-regulate adhesion and proliferation of SF. A. and B. adhesion and C. and D. proliferation of SF (n = 3) after silencing of 
CBP and p300 in absence and presence of TNF (10 ng/ml) was analyzed using real-time cell-based adhesion and proliferation assays (xCelligence System). E. The 
expression of p21 was analyzed by Western blotting, followed by F. densitometric analysis. G. Dead cells were evaluated using the CytoTox-Glo cytotoxicity assay (n 
= 6). *p < 0.05, **p < 0.01. 
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Fig. 6. CBP and p300 regulate the inflammatory response of SF. Heatmaps of selected genes enriched in A. “interferon-response and –signaling”, and “response 
to virus” and C. genes encoding other cytokines and chemokines verified by Real-time PCR in an independent cohort of SF after silencing of CBP and p300 in absence 
and presence of TNF. Mean values of fold expression calculated relative to gap-ctrl are shown (n = 13). B. and D. The secretion of cytokines and chemokines into cell 
culture supernatants was verified by ELISA. E. The levels of H3K27ac in SF treated with C646 or I-CBP were analyzed by Western blotting using the expression of 
α-tubulin as an endogenous control. Representative Western blots are shown. F. densitometric analysis. G. Heatmap of selected inflammatory genes verified by Real- 
time PCR of SF treated with C646 or I-CBP in presence of TNF. Mean values of fold expression calculated relative to unstimulated SF are shown (n = 9–13). *p < 0.05, 
**p < 0.01, ***p < 0.005. 
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only a small amount of CBP and p300 target genes exhibited H3K27ac 
marks in promotors and untranslated gene regions. By silencing of either 
CBP or p300 in unstimulated SF, we verified that CBP and p300 affected 
core functions and pathways of SF. In a previous study addressing in-
dividual functions of CBP and p300 in primary human myoblasts the 
authors concluded, that CBP and p300 controlled complementary sets of 
genes in the same processes [19]. Our findings support a similar 
conclusion regarding the roles of CBP and p300 in SF. Many of the 
pathways we identified in SF were co-regulated by CBP and p300, 
however, both HATs regulated only a subset of overlapping genes and in 
addition exhibited individual functions on target gene levels. In contrast 
to the previous study [19], the pathways and target genes regulated by 
p300 in SF exceeded those regulated by CBP by far, in line with the more 
pronounced effect of p300 silencing on global levels of H3K27ac. 
One of the pathways that was specifically regulated by p300 in SF 
was “limb development”. The crucial role of CBP and p300 in regulating 
developmental pathways is well established and is underscored by the 
death of mice carrying a homozygous deletion of either CBP or p300 at 
early stages of their embryonic development [15]. Several studies have 
highlighted the role of developmental pathways, including Hox, Notch 
and Wnt signaling pathways, in RA and in SF biology [22,33,34]. We 
have previously shown that the expression of HOX transcription factors, 
that determine the embryonic limb development, is maintained in SF 
along the proximal-distal and anterior-posterior body axes and might 
determine the positional disease pattern [22]. Mutations in CBP and 
p300 lead to the Rubinstein-Taybi syndrome, a rare genetic disorder that 
is characterized by growth retardation, microcephaly, dysmorphic facial 
features, and broad thumbs and big toes [37]. The same syndrome was 
caused by a genetic deletion of a region encompassing HOXD13, which is 
differentially expressed in joints of hand and feet along the 
anterior-posterior axes [38], and regulatory elements of this cluster 
[39]. Our data, together with previous findings, indicate that CBP and 
p300 do not only serve as cofactors for HOX transcription factors [40, 
41] but overtake individual functions in regulating their expression. 
CBP/p300 have previously been shown to regulate developmental 
pathways, including components of the Notch and Wnt signaling path-
ways, in double knock out mouse embryonic fibroblasts [42]. The Wnt 
signaling pathway is a main determinant of the bone metabolism in 
arthritis [34]. The Notch signaling pathway has recently been linked to 
the differentiation of perivascular and sublining SF [33], and inhibition 
of Notch1 suppressed the progression of arthritis in vivo [43]. Our data 
point to a major role of p300 and not CBP in regulating these develop-
mental pathways in SF. 
Individual functions of CBP and p300 have also been addressed 
following a different approach in quiescent glioblastoma cells, in which 
the binding of CBP and p300 to the chromatin strongly overlapped in a 1 
kb region up- and downstream of gene bodies. Although there was a high 
overlap in CBP- and p300-regulated pathways, significant differences in 
levels of CBP and p300 binding to the chromatin, as well as potential 
differences in interactions with transcription factors have been detected 
[18]. Results solely based on the recruitment of HATs to chromatin have 
to be handled with care, since recruitment of CBP to chromatin regions 
was not sufficient to predict effects on gene expression of nearby genes 
in mouse embryonic fibroblasts [44]. 45 % of CBP peaks identified in 
this study by ChIPseq were detected in chromatin regions of more than 
50 kb distance to known gene promoters [44], a finding that strongly 
resemble the results of our integrative analysis of p300 RNAseq and 
H3K27ac ChIPseq data sets. We did not detect such an association be-
tween H3K27ac marks and CBP target genes. This might be related to the 
lower number of CBP target genes identified. Another possibility is the 
involvement of other molecular mechanisms beyond the acetylation of 
H3K27, e.g. acetylation of H3K18 or H2B, that might direct 
CBP-dependent gene regulation [12,42]. In line with these previous 
reports, we showed that silencing of CBP and p300 did not only decrease 
global levels of H3K27ac but also affected levels of H3K18ac in SF. 
Our integrative analysis of RNAseq and ChIPseq data could not 
explain the upregulation of genes upon p300 silencing. Although 
H3K27ac is in general considered as an activating histone mark [9], a 
p300-dependent repression of transcription has been described earlier 
[45]. Another explanation for the increased gene expression upon 
silencing of the two HATs might be the involvement of differential 
acetylation of non-histone proteins. A study in mouse embryonic fibro-
blasts estimated that CBP/p300 function accounted for up to one third of 
the nuclear acetylome [42]. 
Chromatin remodeling is a key event in the inflammatory response of 
SF [7,8,46]. In line with a previous study, differences in CBP and p300 
functions became more apparent after stimulation [18]. We showed that 
stimulation of SF with TNF led to a substantial de novo writing of 
H3K27ac, indicating that the inflammatory response of SF is not solely 
based on a re-distribution of enhancers. Loh et al. showed that the 
persistence of the TNF-induced H3K27ac in a ±2 kb region around the 
transcription start site was associated with a sustained expression of 
pro-inflammatory genes in SF. In particular, gene clusters associated 
with a long-lasting H3K27ac in their promoter and proximal enhancer 
regions encoded for cytokines and chemokines [8]. This mechanism 
provided a potential link between the inflammatory gene expression in 
SF and the chronic unremitting synovitis in RA. Previous studies, 
comparing DNA methylation signatures in early, resolving and estab-
lished RA, have indicated that some epigenetic changes occur early in 
disease [47,48]. Among the identified pathways regulated in early and 
established RA that were absent in resolving RA, were integrin, cadherin 
and WNT cell adhesion signaling pathways, components of the actin 
cytoskeleton and antigen presentation [48]. Some of these pathways 
were also enriched in our pathway analysis, suggesting that CBP and/or 
p300 could potentially contribute to reported functional changes of SF in 
early RA [49]. However, to prove this, further studies in samples from 
different disease stages would be needed. Our study was based largely 
on SF derived from established RA. A comparison of effects of CBP and 
p300 silencing in a small number of OA SF has revealed similar effects in 
RA and OA SF. 
Silencing of CBP induced anti-inflammatory effects, and specifically 
down regulated genes associated with an interferon signature. Type I 
interferon signature genes were shown to be associated with disease 
activity in RA and predicted clinical outcome [50]. Silencing of p300 
provoked several pro-inflammatory and pro-destructive effects, indi-
cated by an increased expression of NOTCH1, MMPs and cytokines and 
chemokines. Based on our data obtained by the use of I-CBP we suggest 
an involvement of the bromodomain of p300 in this mechanism. In 
contrast, C646 treatment did not mirror p300 silencing-induced gene 
expression, suggesting that HAT domain and H3K27ac were not 
involved in the increase of gene expression. These data again confirmed 
our integrative analysis of RNAseq and ChIPseq analysis that detected an 
association of down regulated but not up regulated genes after p300 
silencing. Data sets obtained by the use of inhibitors did not fully overlap 
with results obtained by silencing. These differences might be explained 
by either blocking a sole domain by inhibitor treatment, in contrast to 
disrupting protein-protein interactions by removing an entire protein 
that serves as scaffolding platform for several proteins by the silencing 
approach. The molecular basis underlying different functions of CBP and 
p300, and the effects of different inhibitors mirroring more the effects of 
p300 than of CBP, is largely obscure. A comparative mutational analysis 
of the HAT domains of the CBP and p300 revealed some structural dif-
ferences that might underlie individual functions, despite their high 
degree of sequence homology. Whereas the PHD finger of p300 was 
shown to be dispensable for its HAT activity, it was essential for CBP. 
Furthermore, identical mutations impaired HAT activities of CBP and 
p300 differentially [51]. 
5. Conclusion 
We provide new mechanistic insights in how CBP and p300 regulate 
the constitutive and inflammatory response of SF and have identified 
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p300 as the major HAT in SF. Whereas silencing of CBP induced anti- 
inflammatory effects, silencing of p300 provoked pro- and anti- 
inflammatory effects. Inhibitor treatment of SF resembled to a large 
extent effects of p300 silencing, indicating that CBP/p300 inhibitors are 
not sufficient to control the inflammatory response of SF. 
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